



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com


www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)



NQ301

Cat. No.:	HY-101054
CAS No.:	130089-98-4
Molecular Formula:	C ₁₈ H ₁₂ ClNO ₃
Molecular Weight:	325.75
Storage:	<div> <div>Powder</div> <div>-20°C</div> <div>3 years</div> </div> <div> <div></div> <div>4°C</div> <div>2 years</div> </div> <div> <div>In solvent</div> <div>-80°C</div> <div>2 years</div> </div> <div> <div></div> <div>-20°C</div> <div>1 year</div> </div>



SOLVENT & SOLUBILITY

In Vitro	DMSO : ≥ 7.14 mg/mL (21.92 mM) * "≥" means soluble, but saturation unknown.																	
Preparing Stock Solutions	<table><tr><td rowspan="4"><div>Solvent Concentration</div></td><td><div>Mass</div></td><td>1 mg</td><td>5 mg</td><td>10 mg</td></tr><tr><td>1 mM</td><td>3.0698 mL</td><td>15.3492 mL</td><td>30.6984 mL</td></tr><tr><td>5 mM</td><td>0.6140 mL</td><td>3.0698 mL</td><td>6.1397 mL</td></tr><tr><td>10 mM</td><td>0.3070 mL</td><td>1.5349 mL</td><td>3.0698 mL</td></tr></table>	<div>Solvent Concentration</div>	<div>Mass</div>	1 mg	5 mg	10 mg	1 mM	3.0698 mL	15.3492 mL	30.6984 mL	5 mM	0.6140 mL	3.0698 mL	6.1397 mL	10 mM	0.3070 mL	1.5349 mL	3.0698 mL
	<div>Solvent Concentration</div>		<div>Mass</div>	1 mg	5 mg	10 mg												
			1 mM	3.0698 mL	15.3492 mL	30.6984 mL												
			5 mM	0.6140 mL	3.0698 mL	6.1397 mL												
		10 mM	0.3070 mL	1.5349 mL	3.0698 mL													
Please refer to the solubility information to select the appropriate solvent.																		
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 0.71 mg/mL (2.18 mM); Suspended solution; Need ultrasonic																	

BIOLOGICAL ACTIVITY

Description	NQ301 is an antithrombotic agent; inhibits collagen-challenged rabbit platelet aggregation with an IC ₅₀ of 10 mg/mL.
IC ₅₀ & Target	IC ₅₀ : 0.60±0.02 μM (collagen-challenged rabbit platelet aggregation), 0.58±0.04 μM (U46619-challenged rabbit platelet aggregation), 0.78±0.04 μM (arachidonic acid-challenged rabbit platelet aggregation) ^[1]
In Vitro	NQ301 concentration-dependently inhibits collagen (10 mg/mL)-, U46619 (1 mg/mL)- and arachidonic acid (100 mg/mL)- challenged rabbit platelet aggregation, with IC ₅₀ values of 0.60±0.02, 0.58±0.04 and 0.78±0.04 μM, respectively. NQ301 potently suppresses thromboxane B ₂ formation by platelets that are exposed to arachidonic acid in a concentration-dependent manner, but had no effect on the production of prostaglandin D ₂ , indicating an inhibitory effect on thromboxane A ₂ synthase. NQ301 has a potential to inhibit thromboxane A ₂ synthase activity with thromboxane A ₂ /prostaglandin H ₂ receptor blockade, and modulate arachidonic acid liberation as well as 12-hydroxy-5,8,10,14-eicosatetraenoic acid formation in platelets ^[1] . NQ301 inhibits platelet aggregation by suppression of the intracellular pathway, rather than by direct inhibition of fibrinogen-GPIIb/IIIa complex binding. NQ301 significantly inhibits the increase of cytosolic Ca ²⁺

concentration and ATP secretion, and also significantly increases platelet cAMP levels in the activated platelets. The antiplatelet activity of NQ301 may be mediated by inhibition of cytosolic Ca^{2+} mobilization, enhancement of cAMP production and inhibition of ATP secretion in activated platelets^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Cell Assay ^[1]

ashed rabbit platelet suspension is challenged by addition of collagen (10 mg/mL), arachidonic acid (100 μM) or U46619 (1 μM). Concentration- response relationship is determined in the absence or presence of a range of concentrations of NQ301 (0, 0.25, 0.5, 0.75, 1 μM); aspirin-treated platelets (50 μM for 5 min) are used to prevent any possible contribution of endogenous arachidonic acid metabolites to platelet aggregation. The resulting aggregation, measured as the change in light transmission, is recorded for 5 min. The extent of platelet aggregation is expressed as % of the control^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA